Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
CONCLUSIONS: In this pooled data analysis from 3 studies in pediatric patients with HoFH, evolocumab was well tolerated, with no new safety signals reported. These safety findings are consistent with findings from previous studies of evolocumab. Patients showed marked variability in LDL-C reduction. Results from this pooled analysis support guidelines suggesting a trial of PCSK9 inhibitor therapy regardless of estimated residual LDLR function.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01624142, NCT03403374, and NCT02624869.PMID:38545781 | DOI:10.1161/ATVBAHA.123.320268 (Source: Arteriosclerosi...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - March 28, 2024 Category: Cardiology Authors: Frederick J Raal Robert A Hegele Andrea Ruzza J Antonio G L ópez Ajay K Bhatia Johnny Wu Huei Wang Daniel Gaudet Albert Wiegman Jian Wang Raul D Santos Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Atherosclerosis)
Source: Atherosclerosis - March 27, 2024 Category: Cardiology Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort
CONCLUSION: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.PMID:38538465 | DOI:10.1016/j.arcped.2024.01.004 (Source: Archives de Pediatrie)
Source: Archives de Pediatrie - March 27, 2024 Category: Pediatrics Authors: Noel Peretti Alexandre Vimont Emmanuel Mas Julie Lemale Rachel Reynaud Patrick Tounian Pierre Poinsot Liora Restier Fran çois Paillard Alain Pradignac Yann Pucheu Jean-Pierre Rab ès Eric Bruckert Antonio Gallo Sophie B éliard Source Type: research
